| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| X Han, Y B Yuan, X Yu, J P Zhao, C Y Wang, Z Lu, F D Yang, H Dong, Y F Wu, G S Ungvari, Y T Xiang, H F K Chi. The Chinese First-Episode Schizophrenia Trial: background and study design. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. vol 24. issue 4. 2015-07-13. PMID:25482837. |
a total of 600 first-episode schizophrenia patients were randomly divided into 3 groups and treated with risperidone, aripiprazole, and olanzapine for 1 year. |
2015-07-13 |
2023-08-13 |
Not clear |
| Ran Huo, Zhiyun Wei, Yuyu Xiong, Jie Jiang, Yichen Liu, Yucai Yan, Jiajun Shi, Wenqiang Li, Donghong Cui, Qinghe Xing, Lin He, Shengying Qi. Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients. Neuroscience letters. vol 584. 2015-07-06. PMID:25179995. |
association of dopamine receptor d1 (drd1) polymorphisms with risperidone treatment response in chinese schizophrenia patients. |
2015-07-06 |
2023-08-13 |
Not clear |
| Ran Huo, Zhiyun Wei, Yuyu Xiong, Jie Jiang, Yichen Liu, Yucai Yan, Jiajun Shi, Wenqiang Li, Donghong Cui, Qinghe Xing, Lin He, Shengying Qi. Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients. Neuroscience letters. vol 584. 2015-07-06. PMID:25179995. |
the current results provide the first evidence that drd1 polymorphisms may not influence the clinical efficacy of risperidone in chinese schizophrenia patients. |
2015-07-06 |
2023-08-13 |
Not clear |
| Andreas Schreiner, Anders Svensson, Robert Wapenaar, Pierre Cherubin, Patricia Princet, Larisa Serazetdinova, Mathias Zin. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 15. issue 7. 2015-05-27. PMID:24779526. |
long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (inors). |
2015-05-27 |
2023-08-13 |
Not clear |
| Andreas Schreiner, Anders Svensson, Robert Wapenaar, Pierre Cherubin, Patricia Princet, Larisa Serazetdinova, Mathias Zin. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 15. issue 7. 2015-05-27. PMID:24779526. |
to explore differences in outcomes for patients with schizophrenia treated with risperidone long-acting treatment (rlat) or oral antipsychotics (oap). |
2015-05-27 |
2023-08-13 |
Not clear |
| Xueqin Song, Lijuan Pang, Yufang Feng, Xiaoduo Fan, Xue Li, Wei Zhang, Jinsong Gao, Jianjiang Zhang, Katlyn Nemani, Hua Zhang, Luxian L. Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. Behavioral and brain functions : BBF. vol 10. issue 1. 2015-05-27. PMID:25278160. |
fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. |
2015-05-27 |
2023-08-13 |
Not clear |
| Kotaro Hatta, Taro Otachi, Kiyoshi Fujita, Fumiyoshi Morikawa, Shin Ito, Hirofumi Tomiyama, Takayuki Abe, Yasuhiko Sudo, Hiroshi Takebayashi, Toru Yamashita, Shigemasa Katayama, Reiko Nakase, Yutaka Shirai, Chie Usui, Hiroyuki Nakamura, Hiroto Ito, Toyoaki Hirata, Yutaka Saw. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophrenia research. vol 158. issue 1-3. 2015-05-26. PMID:25086659. |
antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. |
2015-05-26 |
2023-08-13 |
Not clear |
| Vicente Molina, Diana Taboada, María Aragüés, Juan A Hernández, Javier Sanz-Fuentenebr. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. Schizophrenia research. vol 158. issue 1-3. 2015-05-26. PMID:25088730. |
greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. |
2015-05-26 |
2023-08-13 |
Not clear |
| Vicente Molina, Diana Taboada, María Aragüés, Juan A Hernández, Javier Sanz-Fuentenebr. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. Schizophrenia research. vol 158. issue 1-3. 2015-05-26. PMID:25088730. |
in this study we assessed the possible relation between cortical thickness in regions of interest selected because of previously reported structural alterations in schizophrenia and clinical and cognitive changes after two years of treatment with risperidone or clozapine in 31 neuroleptic-naïve fe patients with schizophrenia (16 of them treated with clozapine and 15 with risperidone). |
2015-05-26 |
2023-08-13 |
Not clear |
| Vicente Molina, Diana Taboada, María Aragüés, Juan A Hernández, Javier Sanz-Fuentenebr. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. Schizophrenia research. vol 158. issue 1-3. 2015-05-26. PMID:25088730. |
these results may support a positive predictive role for cortical thinning in the frontal region with regard to clinical and cognitive improvement with clozapine and risperidone in fe patients with schizophrenia. |
2015-05-26 |
2023-08-13 |
Not clear |
| Dong-Jing Fu, Cynthia A Bossie, Jennifer Kern Sliwa, Yi-Wen Ma, Larry Alph. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. Clinical schizophrenia & related psychoses. vol 8. issue 2. 2015-05-11. PMID:23446197. |
paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. |
2015-05-11 |
2023-08-12 |
human |
| Peter J Weiden, Leslie Citrome, Gus Alva, Matthew Brams, Ira D Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Linda Pestreich, Marla Hochfeld, Adam Winsec. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24529610. |
a trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. |
2015-04-22 |
2023-08-12 |
Not clear |
| Peter J Weiden, Leslie Citrome, Gus Alva, Matthew Brams, Ira D Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Linda Pestreich, Marla Hochfeld, Adam Winsec. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia research. vol 153. issue 1-3. 2015-04-22. PMID:24529610. |
in a 12-week randomized open-label trial, adults diagnosed with schizophrenia experiencing inadequate efficacy and/or poor tolerability on risperidone, olanzapine, or aripiprazole were randomized to switch to iloperidone either gradually (ie, down-titration of current therapy over the first 2weeks [to 50% on day 1, 25% by week 1, 0% by week 2]) or immediately. |
2015-04-22 |
2023-08-12 |
Not clear |
| R Madelaine Paredes, Marlon Quinones, Ketan Marballi, Xiaoli Gao, Celina Valdez, Seema S Ahuja, Dawn Velligan, Consuelo Walss-Bas. Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. The international journal of neuropsychopharmacology. vol 17. issue 8. 2015-04-14. PMID:24565079. |
we performed a comprehensive metabolomic profiling of 60 schizophrenia patients undergoing treatment with sgas that puts them at high (clozapine, olanzapine), medium (quetiapine, risperidone), or low (ziprasidone, aripiprazole) risk for developing mets, compared to a cohort of 20 healthy controls. |
2015-04-14 |
2023-08-12 |
Not clear |
| Nam Young Lee, Se Hyun Kim, Seong Jin Cho, Young-Cho Chung, In Kwa Jung, Chang Yoon Kim, Duk Ho Kim, Dong Geun Lee, Yo Han Lee, Weon Jeong Lim, Young Suk Na, Sang Eun Shin, Jong-Min Woo, Jin Sang Yoon, Bo-Hyun Yoon, Yong Min Ahn, Yong Sik Ki. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. International clinical psychopharmacology. vol 29. issue 5. 2015-04-07. PMID:24583566. |
a prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in korea. |
2015-04-07 |
2023-08-12 |
Not clear |
| Nam Young Lee, Se Hyun Kim, Seong Jin Cho, Young-Cho Chung, In Kwa Jung, Chang Yoon Kim, Duk Ho Kim, Dong Geun Lee, Yo Han Lee, Weon Jeong Lim, Young Suk Na, Sang Eun Shin, Jong-Min Woo, Jin Sang Yoon, Bo-Hyun Yoon, Yong Min Ahn, Yong Sik Ki. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. International clinical psychopharmacology. vol 29. issue 5. 2015-04-07. PMID:24583566. |
this study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (rlai) in patients with schizophrenia or schizoaffective disorder. |
2015-04-07 |
2023-08-12 |
Not clear |
| Yi-Cheng Hou, Chien-Han La. The response of psychotic symptoms in a patient with resistant schizophrenia under treatment of high-dose risperidone long-acting injection. The Journal of neuropsychiatry and clinical neurosciences. vol 26. issue 3. 2015-04-07. PMID:25093771. |
the response of psychotic symptoms in a patient with resistant schizophrenia under treatment of high-dose risperidone long-acting injection. |
2015-04-07 |
2023-08-13 |
Not clear |
| Pei Jiang, Man-Qin Zhu, Huan-De Li, Yi-Ping Liu, Hua-Lin Cai, Li-Ming Zhan. Effects of vitamin D receptor polymorphisms on the risk of schizophrenia and metabolic changes caused by risperidone treatment. Psychiatry research. vol 215. issue 3. 2015-03-18. PMID:24418047. |
effects of vitamin d receptor polymorphisms on the risk of schizophrenia and metabolic changes caused by risperidone treatment. |
2015-03-18 |
2023-08-12 |
Not clear |
| Mohammad-Reza Khodaie-Ardakani, Omid Mirshafiee, Mehdi Farokhnia, Masih Tajdini, Seyed-Mohammad-Reza Hosseini, Amirhossein Modabbernia, Farzin Rezaei, Bahman Salehi, Habibeh Yekehtaz, Mandana Ashrafi, Mina Tabrizi, Shahin Akhondzade. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry research. vol 215. issue 3. 2015-03-18. PMID:24480077. |
minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. |
2015-03-18 |
2023-08-12 |
Not clear |
| Mohammad-Reza Khodaie-Ardakani, Omid Mirshafiee, Mehdi Farokhnia, Masih Tajdini, Seyed-Mohammad-Reza Hosseini, Amirhossein Modabbernia, Farzin Rezaei, Bahman Salehi, Habibeh Yekehtaz, Mandana Ashrafi, Mina Tabrizi, Shahin Akhondzade. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry research. vol 215. issue 3. 2015-03-18. PMID:24480077. |
the objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. |
2015-03-18 |
2023-08-12 |
Not clear |